secwatch.observer — SEC 8-K summary
======================================

Issuer:     Crinetics Pharmaceuticals, Inc. (CRNX)
CIK:        0001658247
Form:       8-K
Filed at:   2026-07-06T21:17:19+00:00
Accession:  0001140361-26-027642
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vertex to acquire Crinetics for $85/share, ~$10B equity value, adding PALSONIFY and atumelnant
--------------------------------------------------------------------------------

- Vertex to acquire Crinetics for $85.00 per share in cash, total equity value ~$10.0B (~$8.8B net of cash).
- Crinetics' PALSONIFY (once-daily oral for acromegaly) launched in 2025; atumelnant (ACTH receptor antagonist) in Phase 3 for CAH.
- Transaction unanimously approved by both boards; expected to close in Q3 2026, subject to stockholder and regulatory approvals.
- Vertex plans to finance with cash on hand and $4.5B bridge loan from Bank of America and Morgan Stanley.
- Termination fee of ~$350M payable by Crinetics under certain circumstances.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658247/000114036126027642/0001140361-26-027642-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658247/000114036126027642/ef20077399_form8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-027642

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer